Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma.
BACKGROUND
KRAS mutation status is a molecular marker for predicting patient response to treatment with anti-EGFR antibodies (cetuximab and panitumumab) in metastatic colorectal carcinoma. Different approaches may be taken to detect KRAS mutations. There currently are no US Food and Drug Administration-approved assays for the detection of KRAS mutations. For assays that are not approved by the US Food and Drug Administration, the performance characteristics of the assay must be determined and validated by the clinical laboratory before implementation.


OBJECTIVE
To provide an example of how a KRAS mutation-analysis assay may be validated in a clinical laboratory.


METHODS
Describing the approach used by an individual laboratory to compare different assays for validation of KRAS mutation analysis in metastatic colon carcinoma.


RESULTS
Specific validation data are provided, illustrating how a laboratory established assay performance characteristics for KRAS mutation analysis.


CONCLUSIONS
All clinical laboratories must establish several performance specifications mandated by the Clinical Laboratory Improvement Amendments of 1988 before implementation of any laboratory-developed test. Approaches to the validation of such assays may vary among laboratories. We describe an approach used for validation of a KRAS mutation-analysis assay by one laboratory.
Molecular Diagnostics Laboratory, Department of Pathology, The University Health Network, Toronto, Ontario, Canada. suzanne.kamel-reid@uhn.on.ca
Suzanne
S
Kamel-Reid
Tong
T
Zhang
Diane L
DL
Persons
Marina N
MN
Nikiforova
Kevin C
KC
Halling
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary*; D066246:ErbB Receptors / Q000276:immunology*; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000592:standards*; D009154:Mutation / Q000235:genetics*; D000077544:Panitumumab; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D018631:ras Proteins / Q000235:genetics*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068818:Cetuximab